According to the updated diagnostic criteria of the International Myeloma Working Group (IMWG), diagnosis requires ≥10% clonal plasma cells in the bone marrow or biopsy-proven plasmacytoma, plus the presence of “myeloma-defining events,” such as the CRAB criteria (hypercalcemia, renal impairment, anemia, bone lesions) or SLiM criteria (≥60% bone marrow plasma cells, serum free light chain ratio ≥ 100, or ≥1 focal lesion on MRI) [15]. This evidence concerns the gene TNFSF14 and plasma cell myeloma.